These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 1222682)

  • 1. The objective and timing of drug disposition studies, appendix II. Plasma concentrations of oxyphenbutazone in dogs given oxyphenbutazone or the calcium or sodium salts of its phosphate ester.
    Hook RH; Eastwood CJ; Wright GJ
    Drug Metab Rev; 1975; 4(2):249-65. PubMed ID: 1222682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma and serum concentrations of phenylbutazone and oxyphenbutazone in racing Thoroughbreds 24 hours after treatment with various dosage regimens.
    Soma LR; Sams R; Duer W; Tobin T; Woodward C; McDonald J
    Am J Vet Res; 1985 Apr; 46(4):932-8. PubMed ID: 4014842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative pharmacokinetics of phenylbutazone and its metabolite oxyphenbutazone in clinically normal horses and donkeys.
    Mealey KL; Matthews NS; Peck KE; Ray AC; Taylor TS
    Am J Vet Res; 1997 Jan; 58(1):53-5. PubMed ID: 8989496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of bumadizone-, phenylbutazone- and oxyphenbutazone-plasma levels after a single oral dose of phenylbutazone and of bumadizone, respectively (author's transl)].
    Spahn H; Mutschler E; Geissler HE; Faust-Tinnefeldt G
    Arzneimittelforschung; 1981; 31(3):499-503. PubMed ID: 6894380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, metabolism and excretion of phenylbutazone in cattle following intravenous, intramuscular and oral administration.
    Lees P; Ayliffe T; Maitho TE; Taylor JB
    Res Vet Sci; 1988 Jan; 44(1):57-67. PubMed ID: 3375589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma and tissue levels of furosemide in dogs and monkeys following single and multiple oral doses.
    Yakatan GJ; Maness DD; Scholler J; Johnston JT; Novick WJ; Doluisio JT
    Res Commun Chem Pathol Pharmacol; 1979 Jun; 24(3):465-82. PubMed ID: 109903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a new potent heparin. 6th communication: The comparison of the anticoagulant effect of the sodium and calcium salts of a new potent heparin after s.c. injection in beagle dogs.
    Bhargava AS; Schöbel C; Günzel P
    Arzneimittelforschung; 1981; 31(1):79-82. PubMed ID: 7194097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The disposition of radioactivity after administration of the anthelminthic methyl-14C-5-cyclopropylcarbonyl-2-benzimidazole carbamate (ciclobendazole) to rats and dogs.
    Brodie RR; Mayo BC; Chasseaud LF; Hawkins DR
    Arzneimittelforschung; 1977; 27(3):593-8. PubMed ID: 577426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate. 3rd communication: plasma concentrations of the unchanged drug and its deethylated metabolite in rats, dogs and monkeys.
    Nakamura A; Hirota T; Sugihara K; Morino A
    Arzneimittelforschung; 1997 Feb; 47(2):169-74. PubMed ID: 9079236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison of the hematic levels of equiactive doses of oxyphenbutazone in oral and topical administration in experimental phlogosis in the rat].
    Gaggi R; Del Mastro S
    Boll Chim Farm; 1972 Jul; 111(7):434-42. PubMed ID: 5078934
    [No Abstract]   [Full Text] [Related]  

  • 12. [Mechanism of the decrease in free plasma calcium produced by the administration of inorganic phosphates].
    Holguín JA; Peón J; Rule AM; Bárcenas L; Kabela E
    Arch Inst Cardiol Mex; 1981; 51(6):521-8. PubMed ID: 7325743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of human serum albumin with the electrophilic metabolite 1-O-gemfibrozil-beta-D-glucuronide.
    Sallustio BC; Fairchild BA; Pannall PR
    Drug Metab Dispos; 1997 Jan; 25(1):55-60. PubMed ID: 9010630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic studies of cyclocytidine and arabinosylcytosine in dogs.
    Ho DH; Carter CJ; Loo TL; Abbott RL; McBride CM
    Drug Metab Dispos; 1975; 3(4):309-13. PubMed ID: 240662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the mechanisms responsible for the phosphaturia of bicarbonate administration.
    Mercado A; Slatopolsky E; Klahr S
    J Clin Invest; 1975 Dec; 56(6):1386-95. PubMed ID: 172529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of inflammatory adnexal diseases with oxyphenbutazone-prednisolone].
    Bernhart W
    Wien Med Wochenschr; 1970 Sep; 120(37):615-8. PubMed ID: 5502979
    [No Abstract]   [Full Text] [Related]  

  • 17. The time course and effect on serum electrolytes of oral sodium phosphates solution in healthy male and female volunteers.
    Caswell M; Thompson WO; Kanapka JA; Galt DJ
    Can J Clin Pharmacol; 2007; 14(3):e260-74. PubMed ID: 18000319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenylbutazone kinetics and metabolite concentrations in the horse after five days of administration.
    Soma LR; Gallis DE; Davis WL; Cochran TA; Woodward CB
    Am J Vet Res; 1983 Nov; 44(11):2104-9. PubMed ID: 6650958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and metabolism of 14C-oxaceprol in beagle dogs after intramuscular and oral administration.
    Lachmann G; Siegemund B; Kusche W
    Arzneimittelforschung; 1990 Feb; 40(2 Pt 1):200-6. PubMed ID: 2334462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disposition and metabolism of [14C]-haloperidol in rats.
    Miyazaki H; Matsunaga Y; Nambu K; Oh-e Y; Yoshida K; Hashimoto M
    Arzneimittelforschung; 1986 Mar; 36(3):443-52. PubMed ID: 3707663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.